Rophylac Advertising Letter (correction)
This article was originally published in The Pink Sheet Daily
Executive Summary
ZLB Behring received an "untitled" letter from the Center for Biologics Evaluation & Research dated Feb. 3 regarding promotional practices of its IGIV product Rophylac. In a Feb. 7 1article, "The Pink Sheet" DAILY inadvertently categorized it as a "warning" letter
You may also be interested in...
Rhophylac Unapproved Use Claims Targeted In CBER Untitled Letter
ZLB Behring is falsely promoting an unapproved indication for the immune globulin product in an American Hospital Formulary Service fact sheet, FDA says.
Cancer-Genomics Firm Quanticel Debuts With Close Ties To Celgene, And An Exit In Mind
Celgene will get exclusive use of Quanticel's single-cell genomic analysis to tweak its clinical pipeline, and it also has exclusive options to acquire the venture-backed start-up.
One Trial Plus Supportive Evidence Is Enough For Hospital-, Ventilator-Acquired Pneumonia Indication, Panel Says
Anti-Infective Drugs Advisory Committee members viewed one-trial as practical means of gaining efficacy data.